21 research outputs found
Preparing for pandemic influenza: the need for enhanced surveillance.
Link_to_subscribed_fulltex
Recommended adult immunization schedule, United States, 2020
In October 2019, the Advisory Committee on Immunization
Practices (ACIP) voted to approve the Recommended
Adult Immunization Schedule for Ages 19
Years or Older, United States, 2020. The 2020 adult immunization
schedule, available at www.cdc.gov/vaccines
/schedules/hcp/imz/adult.html, summarizes ACIP recommendations
in 2 tables and accompanying notes (Figure).
The full ACIP recommendations for each vaccine are available
at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
The 2020 schedule has also been approved by the director
of the Centers for Disease Control and Prevention
(CDC) and by the American College of Physicians (www
.acponline.org), American Academy of Family Physicians
(www.aafp.org), American College of Obstetricians and
Gynecologists (www.acog.org), and American College of
Nurse-Midwives (www.midwife.org)
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).
This report updates 1999 recommendations by the Advisory Committee on Immunization Practices (ACIP) on the use of influenza vaccine and antiviral agents (MMWR 1999;48[No. RR-4]: 1-29). These recommendations include five principal changes: a) the age for universal vaccination has been lowered to 50 years from 65 years; b) scheduling of large, organized vaccination campaigns after mid-October may be considered because the availability of vaccine in any location cannot be assured consistently in the early fall; c) 2000-2001 trivalent vaccine virus strains are A/Moscow/10/99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Beijing/184/93-like strains; d) information on neuraminidase-inhibitor antiviral drugs has been added; and e) a list of other influenza-related infection control documents for special populations has been added. This report and other information on influenza can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC at .Link_to_subscribed_fulltex
Immunoglobulin M capture immunoassay in investigation of coxsackie B5 and B6 outbreaks in South Australia
Copyright © 1995, American Society for MicrobiologyAn immunoglobulin M (IgM) capture enzyme immunoassay was used to detect major overlapping outbreaks of disease in South Australia caused by coxsackieviruses B5 (CBV-5) and B6 (CBV-6). CBV-5-specific IgM was detected in patients presenting in spring 1992 with acute febrile illnesses, rash, severe acute respiratory disease, meningitis, myocarditis and/or pericarditis, while tests for other viruses were negative. CBV-5 was isolated from an early case. In December 1992 it was noted that CBV-6 had replaced CBV-5 as the major cause of disease. The CBV-6 epidemic continued until April 1993. Serum samples from 495 patients (276 inpatients) were submitted for testing. CBV-6 infection was associated with lower respiratory tract infection and persistent cough. This study demonstrated success of the IgM enzyme immunoassay and the need for diagnostic virology laboratories to look for CBV-6 infection in addition to the other five CBVs